At a glance
- Originator AstraZeneca
- Class Antiplatelets; Ischaemic heart disorder therapies; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unstable angina pectoris
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 08 Sep 1998 Discontinued-II for Unstable angina pectoris in United Kingdom (IV)
- 08 Sep 1998 Discontinued-II for Unstable angina pectoris in United Kingdom (PO)